Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes
(WorldNews Switzerland)

CAMBRIDGE, Mass. and BASEL, Switzerland, April 26, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the United States Patent and Trademarks Office (`USPTO`) is expected to issue a CRISPR/Cas9 genome editing patent to Vilnius University (`Vilnius`). Intellia and CRISPR are nonexclusive sublicensees for a defined field of human therapeutic, prophylactic, and palliative uses (including companion diagnostics), excluding anti-fungal and anti-microbial applications. The Vilnius patent claims are directed to CRISPR/Cas9...